Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 Influenza Season

Overview

Journal MMWR Morb Mortal Wkly Rep

Date 2014 Aug 15

PMID 25121712

Citations 147

Authors

Lisa A Grohskopf

Sonja J Olsen

Leslie Z Sokolow

Joseph S Bresee

Nancy J Cox

Karen R Broder

Ruth A Karron

Emmanuel B Walter

Affiliations

Soon will be listed here.

Abstract

This report updates the 2013 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding use of seasonal influenza vaccines. Updated information for the 2014-15 influenza season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) vaccine dose considerations for children aged 6 months through 8 years; and 3) a preference for the use, when immediately available, of live attenuated influenza vaccine (LAIV) for healthy children aged 2 through 8 years, to be implemented as feasible for the 2014-15 season but not later than the 2015-16 season. Information regarding issues related to influenza vaccination not addressed in this report is available in the 2013 ACIP seasonal influenza recommendations.

Citing Articles

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.

Huang X, Fan T, Li L, Nian X, Zhang J, Gao X Hum Vaccin Immunother. 2022; 18(5):2079924.

PMID: 35714276 PMC: 9621009. DOI: 10.1080/21645515.2022.2079924.

Identification and differential expression of microRNAs in Madin-Darby canine kidney cells with high and low tumorigenicities.

Wang J, Liu L, Yang D, Zhang L, Abudureyimu A, Qiao Z Genes Genomics. 2022; 44(2):187-196.

PMID: 35048333 DOI: 10.1007/s13258-021-01177-x.

Longitudinal Pathways to Influenza Vaccination Vary With Socio-Structural Disadvantages.

Farkhad B, Karan A, Albarracin D Ann Behav Med. 2021; 56(5):472-483.

PMID: 34559192 PMC: 9116583. DOI: 10.1093/abm/kaab087.

City-wide school-located influenza vaccination: A retrospective cohort study.

Benjamin-Chung J, Arnold B, Mishra K, Kennedy C, Nguyen A, Pokpongkiat N Vaccine. 2021; 39(42):6302-6307.

PMID: 34535312 PMC: 8881995. DOI: 10.1016/j.vaccine.2021.08.099.

Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Menne Z, Pliasas V, Compans R, Glover S, Kyriakis C, Skountzou I Virology. 2021; 562:197-208.

PMID: 34375782 PMC: 8479372. DOI: 10.1016/j.virol.2021.08.001.

References

Ochiai H, Shibata M, Kamimura K, NIWAYAMA S . Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines. Microbiol Immunol. 1986; 30(11):1141-9. DOI: 10.1111/j.1348-0421.1986.tb03043.x. View

Ohmit S, Victor J, Teich E, Truscon R, Rotthoff J, Newton D . Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008; 198(3):312-7. PMC: 2613648. DOI: 10.1086/589885. View

Forrest B, Steele A, Hiemstra L, Rappaport R, Ambrose C, Gruber W . A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine. 2011; 29(20):3633-9. DOI: 10.1016/j.vaccine.2011.03.029. View

Ambrose C, Levin M, Belshe R . The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses. 2011; 5(2):67-75. PMC: 3151550. DOI: 10.1111/j.1750-2659.2010.00183.x. View

Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M . Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013; 18(5). DOI: 10.2807/ese.18.05.20388-en. View

. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep. 2013; 62(RR-07):1-43. View

Monto A, Ohmit S, Petrie J, Johnson E, Truscon R, Teich E . Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009; 361(13):1260-7. DOI: 10.1056/NEJMoa0808652. View

Neuzil K, Jackson L, Nelson J, Klimov A, Cox N, Bridges C . Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006; 194(8):1032-9. DOI: 10.1086/507309. View

Kunzel W, GLATHE H, Engelmann H, Van Hoecke C . Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine. 1996; 14(12):1108-10. DOI: 10.1016/0264-410x(96)00061-8. View

10.

Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith D, Klemola T . Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006; 25(10):870-9. DOI: 10.1097/01.inf.0000237829.66310.85. View

11.

Song J, Cheong H, Hwang I, Choi W, Jo Y, Park D . Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine. 2010; 28(23):3929-35. DOI: 10.1016/j.vaccine.2010.03.067. View

12.

Belshe R, Edwards K, Vesikari T, Black S, Walker R, Hultquist M . Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356(7):685-96. DOI: 10.1056/NEJMoa065368. View

13.

Treanor J, Kotloff K, Betts R, Belshe R, Newman F, Iacuzio D . Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999; 18(9-10):899-906. DOI: 10.1016/s0264-410x(99)00334-5. View

14.

Englund J, Walter E, Gbadebo A, Monto A, Zhu Y, Neuzil K . Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006; 118(3):e579-85. DOI: 10.1542/peds.2006-0201. View

15.

Owens G, MacGinnitie A . Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol. 2010; 127(1):264-5. DOI: 10.1016/j.jaci.2010.10.005. View

16.

Erlewyn-Lajeunesse M, Brathwaite N, Lucas J, Warner J . Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009; 339:b3680. DOI: 10.1136/bmj.b3680. View

17.

. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(2):1-64. View

18.

Fleming D, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A . Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006; 25(10):860-9. DOI: 10.1097/01.inf.0000237797.14283.cf. View

19.

Kelso J, Greenhawt M, Li J . Update on influenza vaccination of egg allergic patients. Ann Allergy Asthma Immunol. 2013; 111(4):301-2. DOI: 10.1016/j.anai.2013.07.030. View

20.

Kelso J, Greenhawt M, Li J, Nicklas R, Bernstein D, Blessing-Moore J . Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012; 130(1):25-43. DOI: 10.1016/j.jaci.2012.04.003. View